GMED — Globus Medical Inc
NYSE · Health Care · Health Care
- Latest Close
- $93.83
- 30-Day Move
- +8.2%
- Market Cap
- $9.9B
- Shares Outstanding
- 135,250,000
- P/E Ratio
- 18.41
- P/B Ratio
- 2.57
Analyst consensus: Buy · 22 analysts
Globus Medical Inc
A read-only Alphactor snapshot forGlobus Medical Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$93.83
30-Day Move
+8.2%
Market Cap
$9.9B
Shares Outstanding
135,250,000
P/E Ratio
18.41
P/B Ratio
2.57
$93.83
+8.2%last 90 delayed daily bars
90D High
$101.40
90D Low
$82.01
Avg Volume
1,245,497
Gross margin is running at 67.4%, which gives a quick read on operating quality before you open the full model.
Net margin is 18.3%, useful for comparing GMED against peers in Health Care.
GMED is up 8.2% over the last 30 trading days shown on this page.
Latest operating income is $537M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$144.79
Rule of 40
36.4%
Dark Pool Short %
52.5%
Latest Close
$93.83
30-Day Move
+8.2%
Market Cap
$9.9B
Shares Outstanding
135,250,000
P/E Ratio
18.41
P/B Ratio
2.57
ROE
11.8%
ROA
10.1%
Gross Margin
67.4%
Operating Margin
20.3%
Net Margin
18.3%
Debt / Equity
0
Current Ratio
4.26
Latest Revenue
$2.9B
Revenue
$2.9B
Gross Profit
$2.0B
Operating Income
$537M
Net Income
$538M
Gross Margin
6741.0%
Net Margin
1830.0%
Current Ratio
4.26
Debt / Equity
0.00
Fair Value
$144.79
Upside / Downside
+54.3%
Signal
Undervalued
Implied Growth
3.6%
DCF
$289.70
EPV
$33.02
EV/Rev
$111.66
Growth Assumption
42.2%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$579M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Altman Z
9.77
Safe
Piotroski
9
Strong (7-9)
Cash Conversion
1.40x
Rule of 40
36.4%
Acceptable
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1.0B | $236M | $190M | $104M |
| 2023-12-31 | $1.6B | $201M | $123M | $165M |
| 2024-12-31 | $2.5B | $219M | $103M | $405M |
| 2025-12-31 | $2.9B | $537M | $538M | $579M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$12M
Buys
0
Sells
12
Buy Value
$0
Sell Value
$12M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-25 | Huller Kelly | M | 20,000 | $0.00 |
| 2026-02-25 | Huller Kelly | Sell | 20,000 | $94.50 |
| 2026-02-25 | Huller Kelly | M | 20,000 | $43.58 |
| 2026-02-12 | Huller Kelly | M | 10,000 | $0.00 |
| 2026-02-12 | Huller Kelly | Sell | 10,000 | $87.67 |
| 2026-02-12 | Huller Kelly | M | 10,000 | $45.64 |
| 2026-01-21 | Norwalk Leslie V | A | 15,000 | $0.00 |
| 2026-01-21 | Pfeil Keith W | A | 100,000 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3,598,868 | 0.03% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3,546,492 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2,545,427 | 0.02% | 2025-12-31 |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 2,207,141 | 0.02% | 2025-12-31 |
| J.P. Morgan Fleming Mutual Fd. Group, Inc.-JPMorgan Mid Cap Value Fd. | 1,759,821 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1,436,218 | 0.01% | 2025-12-31 |
| AIM Sector Fd.s -INVESCO VALUE OPPORTUNITIES Fd. | 1,403,820 | 0.01% | 2026-01-31 |
| AIM Sector Funds (Invesco Sector Funds)-INVESCO SMALL CAP VALUE FUND | 1,393,097 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2025-11-14
--
--
Fisher Investments
Filed 2026-02-09
--
--
Vanguard Group
Filed 2026-01-29
$921M
-0.5%
BlackRock
Filed 2024-08-13
$708M
--
Invesco
Filed 2026-02-19
$339M
+1235.2%
Citadel Advisors
Filed 2026-02-17
$222M
--
Geode Capital Management
Filed 2026-02-09
$180M
-0.3%
3.91
Consensus
Buy—
—
—
22
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.